NKNathan M. Krah

Nathan M. Krah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nathan M. Krah has a total of 136 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese mice

    by Nathan M. Krah, Elena Gonzalez-Alvarado, Amog P. Urs, Chinmayee Goda, Yaphet Bustos, James Marvin, Bradley D. Weaver, Spencer Gygi, Ashish Toshniwal, Dennis Towne, et al.

    Obesity expands myeloid progenitors, myelopoiesis and increases the production of monocytes. While weight loss (WL) alleviates aspects of this inflammatory dysregulation, it is not known whether GLP-1 receptor agonists or other traditional modalities of WL differentially modify hematopoietic stem/progenitor cells (HSPCs), hematopoiesis, or inflammatory cell production. To test this, we compared the hematopoietic compartment in lean, obese and weight-reduced mice from tirzepatide treatment and caloric restriction (CR) implemented to match the body weight in both groups. At equal WL, we found CR induced multilineage cytopenias, whereas tirzepatide preserved blood lineages while specifically reducing classical Ly6C hi CCR2 + monocytes. To define the mechanisms underlying these changes we performed single-cell mRNA sequencing of bone marrow HSPCs and mature mononuclear blood cells. CR-HSPCs suppressed gene sets associated with nutrient sensing, proliferation and oxidative phosphorylation (OXPHOS) and exhibited lower inferred cell cycle activity, whereas tirzepatide-HSPCs attenuated these changes. Unlike CR, we found that across progressively differentiated cells from HSPCs to mature blood monocytes, tirzepatide increasingly suppressed OXPHOS and simultaneously shifted the maturation spectrum away from classical monocytes. Following six weeks of tirzepatide withdrawal and weight regain, Ly6C hi CCR2 + monocytes rebounded to levels seen in obese mice. These findings suggest that tirzepatide uncouples WL from the broad hematopoietic suppression seen in CR by preserving progenitor activity but selectively remodeling inflammatory/classical monocytes. We demonstrate that WL modality differentially impacts hematopoietic adaptation and provide evidence that classical monocytes are an effector cell through which tirzepatide may dampen obesity-associated inflammation. Key Points: At equivalent weight loss, calorie restriction causes cytopenias and suppresses HSPC cycling, while tirzepatide preserves these parameters Tirzepatide reduces inflammatory monocytes, shifts maturation, decreases OXPHOS genes, and monocytes rebound after drug withdrawal

  • Open Access

    Publisher Correction: Targeting cancer-specific mutations with RNA-triggered chromatin shredding

    by Jingkun Zeng, Zhiyuan Cheng, Huadong Chen, Zhaojun Wang, Jared Thompson, Kadin T. Crosby, Hesong Han, Arushi Singhal, Wayne Ngo, Chenglong Xia, et al.

  • Open Access

    SLC16A6 is a tyrosine transporter for the melanosome

    by Corey N. Cunningham, Alex J. Bott, Charles H. Adelmann, Matthew Shields, Katarina E. Heyden, Jonathan G. Van Vranken, Álvaro Jesús Narbona-Pérez, Juan A. Cantres-Vélez, Guillaume Adelmant, Nathan M. Krah, et al.

    Cells enable specialized metabolism by compartmentalizing metabolic pathways into distinct organelles, which requires the membrane transport of metabolites. In melanocytes, the amino acid tyrosine is imported into developing melanosomes for the synthesis of the UV-protective pigment melanin 1,2 . In spite of extensive biochemical characterization, the identity of the melanosomal tyrosine transporter remains unknown. Here, we identify SLC16A6 as an orphan melanosome-localized metabolite transporter. Genetic screens reveal that SLC16A6 expression is driven by the SOX10-MITF axis, the well-characterized master regulatory program governing melanogenesis and melanosomal homeostasis 3,4 . By redirecting SLC16A6 to the plasma membrane with an S240A mutation 5 , we demonstrate that SLC16A6 transports tyrosine, a process competitively inhibited by other bulky amino acids. We further determine that SLC16A6 is sufficient for in vitro melanosomal tyrosine uptake. Genetic depletion of SLC16A6 triggered loss of melanosome biogenesis and function as well as depletion of most melanosomal components. Collectively, these findings establish SLC16A6 as a melanosomal tyrosine transporter that is essential for melanosome biogenesis.

  • Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding

    by Jingkun Zeng, Zhiyuan Cheng, Huadong Chen, Zhaojun Wang, Jared Thompson, Kadin T. Crosby, Hesong Han, Arushi Singhal, Wayne Ngo, Chenglong Xia, et al.

    Genetic mutations that drive cancer often occur in tumor suppressor proteins, including the p53 transcription factor which is altered in ~40-50% of cases1,2. However, current therapies fail to target most such mutations because the mutant proteins typically lack defined drug-binding pockets, and restoring the endogenous function has proven challenging. Here, we programmed CRISPR-Cas12a2, an RNA-guided nuclease with trans-nucleolytic cleavage activities3,4, to selectively kill cancer cells by targeting cancer-specific transcripts. This approach limits cell growth by inducing trans shredding of chromatin, triggering DNA damage responses and cell death. Unlike existing methods, RNA-guided Cas12a2 senses cellular RNA signatures, enabling precise targeting of undruggable mutations. Transcript-activated chromatin shredding provides a new approach to precision disease treatments for undruggable targets.


  • Lactate transport inhibition therapeutically reprograms fibroblast metabolism in experimental pulmonary fibrosis

    by David R. Ziehr, Fei Li, K. Mark Parnell, Nathan M. Krah, Kevin J. Leahy, Christelle Guillermier, Ce Gao, Sean A. Prell, Niv Vigder, Sergio Poli, et al.

    Myofibroblast differentiation, essential for driving extracellular matrix synthesis in pulmonary fibrosis, requires increased glycolysis. Although glycolytic cells must export lactate, the contributions of lactate transporters to myofibroblast differentiation are unknown. In this study, we investigated how monocarboxylate transporters (MCTs) 1 and 4, key pulmonary lactate transporters, influence myofibroblast differentiation and experimental pulmonary fibrosis. Our findings revealed that inhibiting MCT1 or MCT4 using RNA interference or small molecules reduced transforming growth factor–β1 (TGFβ)–stimulated myofibroblast differentiation in lung fibroblasts from healthy donors and patients with idiopathic pulmonary fibrosis. Small-molecule MCT inhibitors also decreased bleomycin-induced pulmonary fibrosis in C57Bl6/N mice aged 10 to 12 weeks. Through bioenergetic analyses, stable isotope tracing, metabolomics, and imaging mass spectrometry in both human cells and mice, we demonstrate that inhibiting lactate transport enhanced oxidative phosphorylation, reduced reactive oxygen species production, and diminished glucose metabolite incorporation into fibrotic lung regions. Furthermore, we introduce VB253, an MCT4 inhibitor, which ameliorates pulmonary fibrosis in both young and aged mice, with comparable efficacy to established antifibrotic therapies. These results underscore the necessity of lactate transport for myofibroblast differentiation, identify MCT1 and MCT4 as promising pharmacologic targets in pulmonary fibrosis, and support further evaluation of lactate transport inhibitors as a therapy for patients with limited treatment options.


  • Open Access

    RNA-triggered cell killing with CRISPR–Cas12a2

    by Paul Scholz, Jared Thompson, Kadin T. Crosby, Torsten Fauth, Nathan M. Krah, Grant Schlauderaff, Robin Back, Zachary A. Berkheimer, Alivia Jolley, Dirk Sombroek, et al.

    Selectively eradicating target cells on the basis of their genetic or transcriptional identity remains important in basic research, medicine, biotechnology and agriculture1,2,3. For applications involving bacteria, CRISPR nucleases offer promising options due to their ability to enact RNA-guided counterselection4,5,6,7; however, using these same nucleases for counterselection in eukaryotes has proven much more restrictive8,9,10,11,12,13,14. Here we show that Cas12a2, a recently discovered type V CRISPR nuclease, exhibits RNA-triggered DNA shredding15,16, and enables programmable and sequence-specific elimination of yeast and human cells expressing a target transcript. Triggering Cas12a2 elicits rampant double-stranded DNA breaks in trans, leading to cell death. Cell killing can be activated by a wide range of target transcripts, with no observed off-target activation. Leveraging this approach, we selectively eliminate cells that harbour human papillomavirus, cells that failed to undergo gene editing, or cells that encode a prevalent oncogenic point mutation in KRAS. These findings expand the CRISPR toolbox to allow the selective elimination of eukaryotic cells on the basis of their transcriptional profile.


  • Open Access

    Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base

    by Nathan M. Krah, Rasmus Hoeg, Paul J. Shami, Shannon E. Elf, Lauren E. Lee, Naveen Pemmaraju, Ami B. Patel

  • Type 2 calreticulin mutations activate ATF6 to promote BCL-xL–mediated survival in myeloproliferative neoplasms

    by Nicole S. Arellano, William L. Heaton, Mirielle C. Nauman, Abigail E. Runnels, Jacky Gomez-Villa, Daniele Vanni, Melissa Gaviria, Maihi Fujita, Nathan M. Krah, Michele Ciboddo, et al.

    Most calreticulin (CALR) mutations in myeloproliferative neoplasms are classified as either type 1, a 52–base pair deletion (CALRdel52); or type 2, a 5–base pair insertion (CALRins5). Both are gain-of-function (GOF) mutations that generate an identical mutant C-terminal tail, which mediates the binding to, and activation of, the thrombopoietin receptor myeloproliferative leukemia protein (MPL). We recently reported that despite this shared GOF, CALRdel52 but not CALRins5 mutations cause loss of calcium binding function, leading to activation of, and dependency on, the inositol-requiring enzyme 1/X-box binding protein 1 pathway of the unfolded protein response (UPR). This led us to ask whether CALRins5 mutations activate and depend on a different UPR pathway, and whether this is likewise mediated by a mutation type–specific loss-of-function (LOF). Here, we show that CALRins5 mutations lead to activation of the activating transcription factor 6 (ATF6) pathway of the UPR due to loss of CALR chaperone function. This LOF is caused by interference of the CALRins5 mutant C terminus with key chaperone residue H170. Furthermore, we show that CALRins5 cells are partially dependent on ATF6 for cytokine-independent growth, and identify B-cell lymphoma extra large as a transcriptional target of ATF6 that promotes type 2 CALR-mutant cell survival.


  • A Systematic Review of Health-Related Quality-of-Life Measurement in Patients With Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia

    by Nathan M Krah, Caitlin Fai, Katherine N Sutton, Abigail Rader, Karen D Barton, Lesley A Skalla, Helen W Boucher, Deborah Collyar, Julie Miller, Megan Oakes, et al.

    Background: We conducted a systematic review to gain insight into how health-related quality of life (HRQoL) is measured and reported in hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), common causes of disease and death in hospitalized patients. Methods: Following a prospectively registered protocol in PROSPERO (CRD42021253579), we searched electronic databases, including MEDLINE (PubMed), EMBASE (Elsevier), and CINAHL (EBSCO) from database inception through October 2022 to identify studies measuring HRQoL in patients with HABP and/or VABP. Results: Of 2633 studies identified, 5 articles met our inclusion criteria. Of the 5 included studies, 3 were performed in patients with traumatic brain injury; 4 studies were conducted at a single hospital site, and 1 was from a multicenter registry. Measures to assess HRQoL varied between studies and primarily included the Glasgow Outcome Scale–Extended and the 36-item Short Form. All studies were of mid- to high quality and concluded that HABP/VABP decreased multiple domains of HRQoL, although it was difficult to determine whether this was below the background decrease in HRQoL for comorbid medical conditions. Conclusions: Overall, there is limited measurement of HRQoL in patients with HABP/VABP; however, existing data indicate that HABP/VABP impairs multiple domains of HRQoL. More research is needed to standardize measurements of HRQoL and its application in patients with HABP/VABP.